<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Regulation of myelopoiesis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Regulation of myelopoiesis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Regulation of myelopoiesis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Colin A Sieff, MB, BCh, FRCPath
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter Newburger, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The production of myeloid cells (granulocytes and monocytes) is a tightly regulated process. During steady-state hematopoiesis, approximately 10
         <sup>
          8
         </sup>
         to 10
         <sup>
          9
         </sup>
         of these cells are produced per hour in the bone marrow to maintain their circulating numbers within fairly narrow limits. Production can be rapidly increased in the setting of infection or inflammation. The terms leukocytes and granulocytes are often used interchangeably, although they are somewhat different. The term leukocyte comprises granulocytes, monocytes, and lymphocytes, while the term granulocyte includes polymorphonuclear neutrophils (PMNs), eosinophils, and basophils.
        </p>
        <p>
         Myelopoiesis begins with the differentiation of a small pool of multipotent hematopoietic stem cells into the most primitive myeloid progenitors. These progenitors develop into recognizable myeloid precursors, which subsequently follow a specific differentiation program that culminates in the emergence of mature neutrophils, eosinophils, basophils, and monocytes  (
         <a class="graphic graphic_figure graphicRef52024" href="/z/d/graphic/52024.html" rel="external">
          figure 1
         </a>
         ). This process is most likely driven by expression of successive combinations of transcription factors that in turn dictate the expression of adhesion and hematopoietic growth factor receptors (HGFRs):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adhesion receptors play an important role in the localization and release of maturing cells from specific niches in the bone marrow.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematopoietic growth factors (HGFs), such as stem cell factor (SCF, also called Steel factor or c-kit ligand), interleukin (IL)-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) are important for the amplification of progenitor cells and bind to their target cells through specific receptors.
        </p>
        <p>
        </p>
        <p>
         G-CSF is essential for the amplification and terminal differentiation of neutrophil progenitors and precursors, while macrophage colony-stimulating factor (M-CSF, CSF1) and IL-5 are lineage specific factors for the monocyte and eosinophil lineages, respectively.
        </p>
        <p>
         This topic will review the elements that underlie granulopoiesis and monopoiesis. A general discussion of hematopoiesis and hematopoietic stem cell function is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3536.html" rel="external">
          "Overview of hematopoietic stem cells"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANATOMY OF MYELOPOIESIS
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Granulocyte and macrophage colony-forming cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first colony assays relevant to the study of the production of granulocytes and monocytes in the mouse were described in 1965 and 1966 [
         <a href="#rid1">
          1,2
         </a>
         ]. Analogous assays were then developed for the human system [
         <a href="#rid3">
          3
         </a>
         ]. These studies demonstrated that individual cells derived from mouse spleen or bone marrow could give rise to colonies of up to several thousand differentiated granulocytes and/or macrophages in a soft agar medium. A period of seven to eight days was required for full maturation of these colonies in the mouse compared with 12 to 14 days in humans.
        </p>
        <p>
         Appropriate studies were performed to demonstrate the single cell origin of the colonies. These studies also demonstrated that a single progenitor cell, which was termed the colony-forming unit in culture, or CFU-C, was capable of differentiation into both granulocytes and macrophages, thus the designation CFU-GM. Unit gravity sedimentation and other separation methods have been used to demonstrate that CFU-GM represent a cell population distinguishable from the multipotent stem cell [
         <a href="#rid4">
          4,5
         </a>
         ]. A less restricted myeloid stem cell is referred to as CFU-GEMM because it is the precursor to lineage-specific stem cells for granulocytes, erythrocytes, monocytes, and megakaryocytes  (
         <a class="graphic graphic_figure graphicRef52024" href="/z/d/graphic/52024.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Human granulocyte erythroid monocyte macrophage progenitors (CFU-GEMM) can be identified by markers for CD34 and HLA-DR. Some human myeloid progenitor cells express an additional marker for CD64, the Fc-gamma receptor 1, which identifies a specific progenitor cell dedicated to granulocyte and monocyte development (CFU-GM). Micromanipulation of single progenitor cells or two cells separated after the first cell division show multiple combinations of mature myeloid cells can be derived from these progenitors, supporting a stochastic mechanism for the restriction of differentiation potential [
         <a href="#rid7">
          7,8
         </a>
         ]. The major growth factors required for maturing CFU-GEMM into CFU-GM are stem cell factor (SCF), interleukin (IL)-3, IL-6 (induced by IL-3), Flt3 ligand, and granulocyte-macrophage colony-stimulating factor (GM-CSF)  (
         <a class="graphic graphic_figure graphicRef52024" href="/z/d/graphic/52024.html" rel="external">
          figure 1
         </a>
         ). GM-CSF receptor expression begins in immature precursor cells and is progressively increased during differentiation into mature granulocytes and macrophages [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Long-term liquid bone marrow cultures have been particularly helpful in defining humoral and cell-cell interactions that induce myeloid differentiation [
         <a href="#rid10">
          10
         </a>
         ]. CFU-GM give rise to the more mature granulocyte and macrophage colony-forming units, CFU-G and CFU-M, respectively [
         <a href="#rid1">
          1,2
         </a>
         ]. In addition, CFU-GM can be distinguished from the eosinophil and basophil progenitors, CFU-Eo and CFU-Baso, each arising independently from the common myeloid progenitor cell  (
         <a class="graphic graphic_figure graphicRef52024" href="/z/d/graphic/52024.html" rel="external">
          figure 1
         </a>
         ). CFU-GM, under the influence of SF, IL-3, GM-CSF, G-CSF, and/or M-CSF ultimately gives rise to mature phagocytes, the granulocytes and monocytes.
        </p>
        <p>
         Although a clonogenic assay of granulocyte progenitors was developed almost a decade before the erythroid clonogenic assay, the various factors responsible for granulocyte and monocyte-macrophage development remain incompletely understood.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Neutrophil production and maturation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A model that describes the production and kinetics of human neutrophils suggests that it is highly compartmentalized. The bone marrow contains the most neutrophils (approximately 2.3 x 10
         <sup>
          9
         </sup>
         cells per kg) [
         <a href="#rid11">
          11
         </a>
         ]. In contrast, the peripheral blood pool of neutrophils contains approximately 0.7 x 10
         <sup>
          9
         </sup>
         cells per kg. The relatively tiny peripheral blood pool is divided into two components in equilibrium: the circulating granulocyte pool and the marginating granulocyte pool. These pools provide entrance into the tissues  (
         <a class="graphic graphic_figure graphicRef78149" href="/z/d/graphic/78149.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         The level of circulating cells is buffered by an immense marrow reserve of identifiable precursors. These granulocyte precursors in the bone marrow are also compartmentalized into "mitotic" and "storage" compartments. The mitotic cells are actively dividing (myeloblasts, promyelocytes, and myelocytes), while the storage cells are in a maturing/differentiating, postmitotic state (metamyelocytes, band, and mature neutrophilic forms)  (
         <a class="graphic graphic_figure graphicRef75855" href="/z/d/graphic/75855.html" rel="external">
          figure 3
         </a>
         ). The transit times within each compartment are relatively long, so that a huge reserve remains available.
        </p>
        <p>
         Stages of neutrophil development are characterized by relatively distinct morphological features that are visible in Wright-Giemsa-stained bone marrow aspirates or biopsies viewed by light microscopy. Eosinophils and basophils undergo a similar differentiation program and are first distinguishable at the myelocyte stage when their specific granules are synthesized.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloblast
         </strong>
         – Myeloblasts are the earliest myeloid precursors recognizable by light microscopy  (
         <a class="graphic graphic_picture graphicRef74014" href="/z/d/graphic/74014.html" rel="external">
          picture 1
         </a>
         ). Their size is 15 to 20 microns; their nuclei are large and round with finely granular chromatin and nucleoli; cytoplasm is scant; and cytoplasmic granules are usually absent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Promyelocyte
         </strong>
         – Promyelocytes are larger than myeloblasts (&gt;20 microns)  (
         <a class="graphic graphic_picture graphicRef73480" href="/z/d/graphic/73480.html" rel="external">
          picture 2
         </a>
         ). Their cardinal feature is the presence of many violet-stained (azurophilic; primary) granules with a coarse pattern, often obscuring other structures. The granules are homogenous, dense, and round to ovoid in shape, with a diameter of approximately 0.8 microns. They contain a variety of bactericidal cationic proteins, proteolytic enzymes, and myeloperoxidase [
         <a href="#rid12">
          12-14
         </a>
         ]. Other cellular features (nuclei, nuclear chromatin, nucleoli) are similar to myeloblasts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myelocyte
         </strong>
         – Myelocytes are the last precursor capable of undergoing cell division  (
         <a class="graphic graphic_picture graphicRef54089" href="/z/d/graphic/54089.html" rel="external">
          picture 3
         </a>
         ). They undergo three divisions that result in progressively smaller cells with secondary (specific) granules in addition to the primary granules present at the promyelocyte stage. The specific granules are approximately 0.5 microns in diameter, less dense and more numerous than primary granules, and difficult to see by light microscopy. They contain adhesive proteins such as lactoferrin, integrins, binding protein for cobalamin, and other distinguishing markers as outlined in the table  (
         <a class="graphic graphic_table graphicRef57400" href="/z/d/graphic/57400.html" rel="external">
          table 1
         </a>
         ). Their nuclei become progressively smaller and more irregularly shaped with each division; nuclear chromatin becomes coarse and more clumped, and nucleoli are sparse to absent. The nuclear to cytoplasmic ratio is reduced.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metamyelocyte
         </strong>
         – Metamyelocytes are post-mitotic cells that are slightly smaller than myelocytes and have indented nuclei  (
         <a class="graphic graphic_picture graphicRef59197" href="/z/d/graphic/59197.html" rel="external">
          picture 4
         </a>
         ). Their cytoplasm is uniformly pink with finely dispersed granules, similar to that of bands and mature PMNs. Nuclear chromatin is coarse, clumped, and peripherally condensed; nucleoli are absent. Polyribosomes and endoplasmic reticulum (required for protein synthesis and maturation) are also absent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Band
         </strong>
         – Bands (also called stabs; juvenile forms) are smaller cells with elongated, horseshoe-shaped nuclei  (
         <a class="graphic graphic_picture graphicRef82140" href="/z/d/graphic/82140.html" rel="external">
          picture 5
         </a>
         ). Their nuclear chromatin is aggregated into evenly arranged clumps. Their cytoplasm is like that of mature PMNs, with pink staining and fine azure/bluish granules. Based on cytochemistry, the ratio of azurophilic primary granules to specific secondary granules is approximately 1:2 [
         <a href="#rid15">
          15
         </a>
         ]. Tertiary (gelatinase) granules are also present. Bands are fully functional phagocytes and may account for 3 to 5 percent of the differential count. They are included in the absolute neutrophil count (ANC) (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polymorphonuclear cell (PMN)
         </strong>
         – PMNs (also called segmented neutrophils) are the fully mature stage of neutrophil development  (
         <a class="graphic graphic_picture graphicRef60666" href="/z/d/graphic/60666.html" rel="external">
          picture 6
         </a>
         ). These cells are of uniform size (13 microns in diameter). Nuclei are segmented into two to five lobes (average, three) connected by thin chromatin strands. Nuclear chromatin is coarse and clumped, and stains deep purple. Approximately 3 percent of PMNs from females have a visible Barr body (inactivated X chromosome, visible as a drumstick-shaped mass of dense chromatin 1.5 microns in size, attached to one nuclear lobe by a slender filament) [
         <a href="#rid16">
          16
         </a>
         ]. The cytoplasm contains fine azure/bluish granules and prominent secondary granules, which are finely dispersed and stain the cytoplasm faintly pink. Peroxidase staining reveals peroxidase-positive primary granules and peroxidase-negative secondary granules. Granule heterogeneity is obvious by electron microscopy  (
         <a class="graphic graphic_picture graphicRef74658" href="/z/d/graphic/74658.html" rel="external">
          picture 7
         </a>
         ). Mitochondria are scant, and abundant glycogen is present, as the cell depends on anaerobic glycolysis for generating ATP.
        </p>
        <p>
        </p>
        <p>
         Distinction among these stages is often helpful in evaluating and characterizing myeloid malignancies. (See
         <a class="medical medical_review" href="/z/d/html/4434.html" rel="external">
          "Evaluation of bone marrow aspirate smears", section on 'High power examination of the marrow'
         </a>
         .)
        </p>
        <p>
         The kinetics of proliferation of recognizable cell precursors have been evaluated using labeled precursors of DNA. These studies indicate that the maturation time for neutrophils from the myeloblast stage is about eight days  (
         <a class="graphic graphic_figure graphicRef75855" href="/z/d/graphic/75855.html" rel="external">
          figure 3
         </a>
         ). The so-called labeling indices from which measurements of cell cycle times can be made have served as important approaches to the study of the pharmacology and toxicity of chemotherapy.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Release of neutrophils into the blood compartment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The final stage of granulocyte production, their release from the marrow, is also multifaceted [
         <a href="#rid17">
          17
         </a>
         ]. At least four factors may influence granulocyte egress:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The organization and localization of the cells in relation to vascular channels
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The development of nuclear and cytoplasmic changes that increase cell deformability
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factors such as chemokines, cytokines, microbial products, and other inflammatory mediators [
         <a href="#rid18">
          18
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia", section on 'Mechanisms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia", section on 'Inflammation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The regulation of blood flow through vascular channels in the marrow
        </p>
        <p>
        </p>
        <p>
         The half-life of neutrophils in peripheral blood has been estimated to be 19 hours [
         <a href="#rid19">
          19
         </a>
         ]. Neutrophils then leave the bloodstream and enter tissues to localize at sites of inflammation  (
         <a class="graphic graphic_figure graphicRef78149" href="/z/d/graphic/78149.html" rel="external">
          figure 2
         </a>
         ). They interact with the endothelial cells through the integrin receptors, CD11a (LFA-1), CD11b (Mac-1), CD11c (gp150/95), which share a common beta-2 integrin subunit, CD18 [
         <a href="#rid20">
          20
         </a>
         ]. Neutrophils from patients with a total or partial absence of these beta-2 dimeric integrin complexes on the neutrophil surface cannot leave the circulation; patients with leukocyte adhesion deficiency l (LAD l) have a marked neutrophil and monocyte leukocytosis and recurrent pyogenic infections. Other defects in selectin fucosylation and other integrins have been described [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Regulation of neutrophil release
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanisms that control release of PMNs from the bone marrow are only partially understood. A variety of compounds induce PMN movement into the circulation, including endotoxin, glucocorticoids, a leukocyte-mobilizing factor derived from the third component of complement (C3e), chemoattractants such as C5a, cytokines such as tumor necrosis factor (TNF)-alpha, and certain androgens [
         <a href="#rid22">
          22-26
         </a>
         ]. To emerge into the circulation, PMNs must deform and migrate to the luminal side of the endothelial sinusoidal surface. Endotoxin affects the relationship between marrow sinus endothelial cells and the stromal macrophages covering nonluminal sinusoidal surfaces; it induces retraction of macrophages away from the endothelium which facilitates contact between PMNs and endothelial cells and allows PMN egress from the bone marrow [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
         In vitro, PMNs and bands readily pass through filters with pore sizes of 1 micron in response to chemoattractants. Metamyelocytes and late myelocytes are impaired in these responses, whereas early myelocytes, promyelocytes, and myeloblasts cannot move or deform [
         <a href="#rid27">
          27,29
         </a>
         ]. Blood viscosity at high flow rates is a function of cell deformability and volume. As a result, viscosity increases dramatically in patients with markedly increased numbers of circulating leukemic blasts (eg, white blood cell [WBC] count &gt;400,000/microL); this problem does not occur with similar WBC counts due to neutrophils rather than blasts [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         G-CSF is the principal cytokine that stimulates release of neutrophils from the bone marrow, but the mechanisms that mediate these effects are incompletely defined. SDF-1 (CXCL12), a factor expressed by stromal cells (eg, stromal osteoblasts), and CXCR4, its ligand that is expressed by neutrophils, may play a key role in mediating retention of neutrophils in bone marrow. G-CSF administration leads to a reduction in SDF-1 expression and CXCR4 cleavage [
         <a href="#rid31">
          31,32
         </a>
         ]. In addition, G-CSF increases expression of CXCL2, which is expressed by endothelial cells and binds to its receptor CXCR2 on neutrophils, attracting their migration toward the sinusoidal endothelium [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         The functional importance of these molecules is illustrated by WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis), in which mutations of CXCR4 cause retention of mature neutrophils in the bone marrow [
         <a href="#rid33">
          33
         </a>
         ], as described separately. (See
         <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">
          "Congenital neutropenia", section on 'WHIM syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H100891">
         <span class="h2">
          Neutrophil fate
         </span>
         <span class="headingEndMark">
          —
         </span>
         The turnover rate for PMNs is estimated at 0.3 to 1.3 x 10
         <sup>
          9
         </sup>
         cells per kg per day [
         <a href="#rid34">
          34
         </a>
         ]. Studies in healthy volunteers suggest a mean lifespan of approximately five to eight days [
         <a href="#rid35">
          35
         </a>
         ]. The disappearance of labeled PMNs follows a single exponential curve, implying that PMNs are destroyed or leave the blood randomly rather than according to their age (senescence), as is true for erythrocytes and platelets.
        </p>
        <p>
         The fate of neutrophils includes apoptosis and macrophage engulfment. One candidate for a molecular trigger of apoptosis in PMNs is the product of the FAS (CD95) gene. Fas protein is expressed on the PMN surface, and PMNs constitutively release Fas ligand [
         <a href="#rid36">
          36
         </a>
         ]. Since Fas ligand induces apoptosis in PMNs, its release may provide a paracrine pathway that mediates PMN death [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Fas-mediated PMN apoptosis is suppressed in vitro by biologic molecules and drugs (eg, G-CSF, GM-CSF, IL-3, IL-6, IL-15, glucocorticoids) [
         <a href="#rid37">
          37-39
         </a>
         ]. Mediators of inflammation, such as endotoxin, human recombinant C5a, TNF-alpha, and interferon gamma, also inhibit PMN apoptosis in a concentration dependent fashion in vitro [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         When PMNs become apoptotic in the circulation, CXCR4 is again expressed on their surface and they return to the bone marrow where they are phagocytosed by stromal macrophages. This in turn stimulates G-CSF production, increasing production of PMNs [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Under normal conditions, PMNs exit the circulation randomly, followed by their death at inflammatory sites over the following two to three days. Cell death is by a combination of apoptosis and macrophage engulfment [
         <a href="#rid41">
          41
         </a>
         ]. PMNs that transit into the tissues do not return to the circulation.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Monocytes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monocytes irreversibly leave the circulation [
         <a href="#rid42">
          42,43
         </a>
         ] and differentiate further into fixed-tissue macrophages, a category comprising alveolar macrophages [
         <a href="#rid44">
          44
         </a>
         ], hepatic Kupffer cells [
         <a href="#rid45">
          45
         </a>
         ], dermal Langerhans' cells [
         <a href="#rid46">
          46
         </a>
         ], osteoclasts [
         <a href="#rid47">
          47
         </a>
         ], peritoneal and pleural macrophages, and perhaps brain microglial cells [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Dendritic cells (DCs), which bridge the gap between innate and adaptive immune responses, can be derived from granulocyte monocyte progenitors (GMP) at steady state, and include classic DCs (cDC1 and cDC2) and plasmacytoid DCs (pDC). These pDCs have efficient foreign antigen processing capacity and therefore greater T cell stimulating activity. Multipotent progenitors (MPP) give rise to lymphoid-primed multi-potent progenitors (LMPP) that are IL7R+ and also differentiate into pDCs and are less efficient at antigen processing and T cell stimulation than myeloid derived pDCs but have a greater capacity to produce IFN. They also have a 5 to 10 times higher output than the pDCs derived from GMPs. This appears to explain why pDC are more lymphoid in their expression of RAG and rearranged IgH loci, while cDC1s express myeloid antigens that distinguish them from monocytes and cDC2 share the majority of their markers with mo-DC [
         <a href="#rid49">
          49-52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          REGULATORS OF MYELOPOIESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The enormous diversity of the myeloid system, the high turnover rate of granulocytes, and the necessity to maintain splenic, marginated, and bone marrow granulocyte pools to meet sudden demands caused by infection has led to the evolution of an extremely complex regulatory network. Many of the factors that allow release of granulocytes from storage pools are distinct from colony-stimulating factors (CSFs) [
         <a href="#rid17">
          17
         </a>
         ]. In addition, granulocyte-macrophage CSF (GM-CSF) can inhibit granulocyte motility [
         <a href="#rid53">
          53
         </a>
         ] and can activate granulocytes to increase superoxide anion generation [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         This complexity in vivo has not permitted studies analogous to those in which erythropoiesis is influenced by hypertransfusion or hemorrhage and megakaryocytopoiesis is stimulated by induced thrombocytopenia; however, in vivo studies using antibodies to neutrophils, germ-free animals, and tissue specific knockouts of regulatory components have begun to provide novel insights into the process by which both emergency and steady-state myelopoiesis are regulated. (See
         <a class="local">
          'Myelopoietic feedback loops'
         </a>
         below.)
        </p>
        <p>
         In early work, investigators relied heavily upon in vitro progenitor assays to study the regulation of myelopoiesis. Both transcription factors and growth factors play an important role in this process and their individual effects have been determined in part by the generation of mice lacking genes for specific proteins  (
         <a class="graphic graphic_table graphicRef67668" href="/z/d/graphic/67668.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">
          "Regulation of erythropoiesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6673.html" rel="external">
          "Biology and physiology of thrombopoietin"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Transcription factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myeloid transcription factors play a major role in regulating the expression of myeloid specific genes and are therefore important for commitment to the myeloid lineage and for normal myeloid differentiation. Whether the transcription factors themselves are regulated by environmental or intrinsic signals is still a major unanswered question. It appears that, once induced, their transcription can often be amplified by autoregulatory loops, and that the factors frequently act in subtle combinatorial mechanisms to induce different myeloid genes [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         The occupancy of regulatory regions of lineage-specific genes also depends on chromatin configuration and methylation status. There is evidence that during myelopoiesis these epigenetic changes occur in a step-wise manner; in primitive cells lysozyme gene regulatory sites are transiently occupied, whereas in mature macrophages much more stable occupancy is attained at the time that the gene becomes maximally expressed [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          PU.1
         </span>
         <span class="headingEndMark">
          —
         </span>
         The PU.1 transcription factor is a member of the Ets family and is expressed principally in monocytes/macrophages and B lymphocytes, and also in erythroid cells and granulocytes [
         <a href="#rid58">
          58,59
         </a>
         ]. Potential target genes include the integrin CD11b, M-CSF receptor, GM-CSF receptor alpha, G-CSF receptor, and the Igl light chain [
         <a href="#rid60">
          60-64
         </a>
         ]. Mice that lack PU.1 die in utero with absence of monocytes, granulocytes, and T and B lymphocytes; anemia is variable and therefore does not explain the prenatal mortality [
         <a href="#rid65">
          65
         </a>
         ]. On the other hand, mice with severely reduced expression of Pu.1 (ie, Pu.1 knockdown mice) develop acute myeloid leukemia [
         <a href="#rid66">
          66,67
         </a>
         ] and heterozygous deletion of the Pu.1 locus has been associated with acute myeloid leukemia in humans [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          C/EBP family
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CCAAT/enhancer binding protein (C/EBP) family of transcription factors bind to DNA through a basic region-leucine zipper domain (bZIP). There are several family members (C/EBP-alpha [CEBPA], C/EBP-beta [CEBPB; also called NF-IL-6], C/EBP-gamma (CEBPG), C/EBP-delta [CEBPD], and C/EBP-epsilon [CEBPE]) that are differentially expressed during myelopoiesis [
         <a href="#rid69">
          69
         </a>
         ]. During maturation of a myeloid precursor cell line to terminally differentiated granulocytes, there was an increase (CEBPB and CEBPE), or an increase followed by either a partial (CEBPD) or marked (CEBPA) reduction in the level of expression of members of this family [
         <a href="#rid70">
          70,71
         </a>
         ]. In one study of 408 patient samples and five cell lines representing 11 different malignancies, mutation of
         <em>
          CEBPA
         </em>
         was noted in acute myeloid leukemia and myelodysplasia, but rarely in other malignancies [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         The functions of the different members of C/EBP family have been delineated by target disruption of specific genes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CEBPA
         </strong>
         – CEBPA has been implicated in the regulation of hepatocyte, adipocyte, and myeloid differentiation (levels are low in undifferentiated dividing cells but high in quiescent terminally differentiated cells), and also in myeloid CSF receptor promoter function [
         <a href="#rid73">
          73,74
         </a>
         ]. Cebpa-deficient mice die within the first few hours after birth from impaired glucose metabolism; they also have a selective block in granulocyte production leading to the absence of mature granulocytes and a profound and selective reduction in G-CSF receptor mRNA expression and in CFU-G [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CEBPB
         </strong>
         – Mice that lack Cebpb produce monocytes that are defective in bactericidal and tumoricidal function; in addition, their macrophages and fibroblasts, but not their endothelial cells, fail to produce G-CSF in response to lipopolysaccharide (LPS) [
         <a href="#rid76">
          76
         </a>
         ]. In another study, Cebpb-deficient mice had an increase in IL-6 production and enhanced proliferation of a number of hematopoietic lineages, a syndrome that resembles Castleman disease [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CEBPE
         </strong>
         –Mice with null mutations of
         <em>
          Cebpe
         </em>
         develop normally but die from opportunistic infections at three to five months of age because of functional abnormalities of neutrophils and eosinophils [
         <a href="#rid78">
          78
         </a>
         ]. Cebpe-null neutrophils fail to develop specific granules or their content proteins, and have defects in chemotaxis, respiratory burst generation, and phagocytosis. These observations led to the demonstration that patients with specific granule deficiency, a rare disorder of neutrophil function associated with increased infections, was caused by mutations in the
         <em>
          CEBPE
         </em>
         gene. The mice also develop a terminal myelodysplasia with proliferation of atypical granulocytes, although it was not clear whether this was truly a clonal disorder or a response to chronic infection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Core binding factor family
         </span>
         <span class="headingEndMark">
          —
         </span>
         The core binding factor (CBF) family is another group of transcription factors that plays an important role in the regulation of myeloid specific promoters such as those for the myeloperoxidase (
         <em>
          MPO
         </em>
         ) and neutrophil elastase (
         <em>
          HNE
         </em>
         ) genes. These were first identified on the basis of their ability to bind to the polyomavirus enhancer-binding protein 2/core binding factor (PEBP2/CBF). Two alpha subunits (RUNX1; formerly called AML1 or CBF-alpha-1 and CBF-alpha-2), bind DNA with low affinity, but the affinity is strengthened in the presence of the non-DNA-binding beta subunit (CBFB; also called CBF-beta). In addition, RUNX1 can act synergistically with CEBPA to activate the M-CSF receptor promoter [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Mice lacking Runx1 die in utero by day 12.5 due to hemorrhage, and they fail to produce all definitive hematopoietic lineages [
         <a href="#rid79">
          79,80
         </a>
         ]. Similar defects have been observed in CBF-beta knockout mice [
         <a href="#rid81">
          81
         </a>
         ]. It has been suggested that RUNX1 and CBFB are required for the emergence of definitive hematopoietic stem cells in the embryo; both genes are also required in the later stages of differentiation of some hematopoietic lineages (megakaryocytes, T and B cells) [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         These two genes also play a role in leukemogenesis [
         <a href="#rid82">
          82,83
         </a>
         ].
         <em>
          RUNX1
         </em>
         is involved in the most frequent chromosome translocation in acute myeloid leukemia, t(8;21)(q22;q22), which results in the production of the RUNX1::RUNX1T1 (formerly called AML/ETO) fusion protein [
         <a href="#rid84">
          84-88
         </a>
         ], while CBFB is involved in a chromosome inversion inv(16)(p13;q22) that is associated with AML with aberrant eosinophils [
         <a href="#rid89">
          89
         </a>
         ]. The abnormal RUNX1::RUNX1T1 protein can act as a dominant negative inhibitor of RUNX1 [
         <a href="#rid90">
          90-92
         </a>
         ]. However, murine knock-in studies suggest that the mechanism may be more complex. Mice heterozygous for the corresponding gene fusion have a severe block in hematopoiesis, but yolk sac cells generate CFU-M whereas yolk sac cells from Runx1 or Cbfb-knockout mice contain no colony-forming cells [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         Experiments in mice have demonstrated that Runx1 binds to functionally important sites within the Pu.1 upstream regulatory element and regulates Pu.1 expression at both embryonic and adult stages of development [
         <a href="#rid94">
          94
         </a>
         ]. (See
         <a class="local">
          'PU.1'
         </a>
         above.)
        </p>
        <p>
         Additional evidence for the importance of RUNX1 in myelopoiesis comes from an understanding of Familial AML with mutated
         <em>
          CEBPA
         </em>
         (familial platelet disorder with predisposition to myelodysplasia and/or acute myeloid leukemia). This is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, decreased megakaryocyte colony formation, and an approximately 37 percent incidence of AML. Nonsense mutations or intragenic deletion of
         <em>
          RUNX1
         </em>
         have been seen in this condition. (See
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial AML with mutated CEBPA'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4502.html" rel="external">
          "Acute myeloid leukemia: Molecular genetics", section on 'Familial AML'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Retinoic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinoic acid (RA) may play a direct role in myelopoiesis as evidenced by the following observations: vitamin A deficiency is associated with defective hematopoiesis; RA can induce myeloid differentiation in cell lines and in primary leukemic cells; and
         <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">
          all-trans retinoic acid
         </a>
         is often effective in the treatment of acute promyelocytic leukemia (APL). (See
         <a class="medical medical_review" href="/z/d/html/4527.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults"
         </a>
         .)
        </p>
        <p>
         The leukemic cells of almost all patients with APL have a balanced (15;17) translocation involving the
         <em>
          PML
         </em>
         gene on chromosome 15 and
         <em>
          RARA
         </em>
         (retinoic acid receptor-alpha) gene on chromosome 17. The PML::RARA fusion protein associated with this translocation in APL is an abnormal RAR with altered DNA binding and transcriptional activities, thereby preventing differentiation of promyelocytes. A similar effect, blocked differentiation at the promyelocyte stage, can be induced by expression of a dominant negative RAR in a multipotent murine hematopoietic cell line and in normal mouse bone marrow cells; this effect can be overcome by high concentrations of RA [
         <a href="#rid95">
          95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4523.html" rel="external">
          "Molecular biology of acute promyelocytic leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Growth factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of growth factors also play a major role in myelopoiesis, including IL-3, GM-CSF, G-CSF, and M-CSF [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Effects on progenitor cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following observations have been made in murine and human studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Murine IL-3 stimulates a broad spectrum of myeloid progenitor cells including CFU-GM, CFU-G, CFU-M, CFU-Eo, erythroid burst-forming units (BFU-E), megakaryocyte CFU (CFU-Meg) and mast cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As its name implies, GM-CSF was initially thought to provide a more restricted stimulus to the proliferation and development of CFU-GM. However, murine studies with purified or recombinant GM-CSF have shown that it also stimulates the initial proliferation of other progenitors such as BFU-E [
         <a href="#rid97">
          97,98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The other murine factors, G-CSF and M-CSF are more restricted and predominantly stimulate granulocyte and monocyte colony forming units (CFU-G and CFU-M), respectively [
         <a href="#rid99">
          99,100
         </a>
         ]. However, combinations of stem cell factor (SCF) and G-CSF enhance progenitor cells of multiple lineages in blast colonies, indicating a broader action on primitive progenitor cells [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The importance of G-CSF as a myelopoietic growth factor was revealed in mice with deletion of the G-CSF gene [
         <a href="#rid102">
          102
         </a>
         ]. These mice have a chronic neutropenia (20 to 30 percent of normal levels) and reduced bone marrow myeloid precursors and progenitors. They also have a markedly impaired capacity to increase neutrophil and monocyte counts after infection with
         <em>
          Listeria
         </em>
         <em>
          monocytogenes
         </em>
         .
        </p>
        <p>
         With the possible exception of GM-CSF, the activities of the human CSFs are similar to those of the corresponding murine factors. Both IL-3 and GM-CSF affect a similar broad spectrum of human progenitor cells including CFU-GEMM, CFU-GM, CFU-G, CFU-M, CFU-Eo, and CFU-Meg  (
         <a class="graphic graphic_figure graphicRef52024" href="/z/d/graphic/52024.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Effects on mature cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to their effects on progenitor differentiation, the colony-stimulating factors also induce a variety of functional changes in mature cells. As an example, GM-CSF inhibits polymorphonuclear neutrophil migration under agarose [
         <a href="#rid103">
          103
         </a>
         ], induces antibody dependent cytotoxicity (ADCC) for human target cells [
         <a href="#rid53">
          53
         </a>
         ], and increases neutrophil phagocytic activity [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Some of the functional changes in mature cells may be related to a GM-CSF-induced increase in cell surface expression of a family of antigens that function as cell adhesion molecules [
         <a href="#rid104">
          104
         </a>
         ]. The increase in antigen expression of CD11b and CD11c is rapid and is associated with increased aggregation of neutrophils; both are maximal at the migration inhibitory concentration of 500 pmol/L, and granulocyte-granulocyte adhesion can be inhibited by an antigen-specific monoclonal antibody. GM-CSF also acts as a potent stimulus of eosinophil ADCC, superoxide production, and phagocytosis [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
         G-CSF and M-CSF also affect mature cells. G-CSF acts as a potent stimulus of neutrophil superoxide production, chemotaxis, ADCC, and phagocytosis [
         <a href="#rid106">
          106,107
         </a>
         ], while M-CSF activates mature macrophages [
         <a href="#rid108">
          108
         </a>
         ] and enhances macrophage cytotoxicity.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          GM-CSF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insight into the in vivo role of GM-CSF comes from studies in mice that carried two null alleles of the GM-CSF gene [
         <a href="#rid109">
          109,110
         </a>
         ]. These mice had normal basal hematopoiesis but developed progressive accumulation of surfactant lipids and proteins in the alveolar space, the defining characteristic of idiopathic human pulmonary alveolar proteinosis. Extensive lymphoid hyperplasia associated with lung airways and blood vessels was also found. (See
         <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">
          "Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults"
         </a>
         .)
        </p>
        <p>
         Surfactant proteins and lipids are synthesized by type II pneumocytes and cleared from the alveolar space by type II cells and by alveolar macrophages. The lungs from the null animals showed normal surfactant synthetic capacity and no accumulation in type II pneumocytes. In contrast, the alveolar macrophages showed a marked increase in surfactant protein and lipid, suggesting strongly that these cells cannot process surfactant in the absence of GM-CSF.
        </p>
        <p>
         Similar pulmonary pathology is seen in mice with null mutations of the common chain of the GM-CSF/IL-3/IL-5 receptor (beta c) [
         <a href="#rid102">
          102,111
         </a>
         ]. These mice also have low basal numbers of eosinophils and absence of blood and lung eosinophilia in response to infection with the parasite
         <em>
          Nippostrongylus brasiliensis
         </em>
         .
        </p>
        <p>
         Human pulmonary alveolar proteinosis (PAP) is now known to be due to autoantibodies to GM-CSF in the majority of patients [
         <a href="#rid112">
          112
         </a>
         ], while a small number of patients have mutations in the alpha chain of the GM-CSF receptor [
         <a href="#rid113">
          113,114
         </a>
         ] or the common beta chain of the IL-3/GM-CSF/IL-5 receptor [
         <a href="#rid115">
          115
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">
          "Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults", section on 'Definitions and classification'
         </a>
         .)
        </p>
        <p>
         Innate and adaptive immune responses in rheumatoid arthritis (RA) lead to infiltration of synovial tissue with leukocytes that release TNF, IL-6, GM-CSF, and other cytokines into the tissues. This response attracts other inflammatory cells that mediate tissue damage [
         <a href="#rid116">
          116
         </a>
         ]. GM-CSF levels are increased in the plasma of RA patients and are highly elevated in synovial fluid. These observations have led to investigational studies in RA of monoclonal antibodies directed against the GM-CSF receptor (eg, mavrilimumab, namilumab) [
         <a href="#rid117">
          117,118
         </a>
         ].
        </p>
        <p>
         Innate and adaptive immune responses in rheumatoid arthritis (RA) lead to infiltration of synovial tissue with leukocytes that release TNF, IL-6, GM-CSF and other cytokines into the tissues. This response attracts other inflammatory cells that mediate tissue damage [
         <a href="#rid116">
          116
         </a>
         ]. GM-CSF levels are increased in the plasma of RA patients and are highly elevated in synovial fluid; these observations have led to exploration of monoclonal antibodies against GM-CSF receptor in this setting [
         <a href="#rid117">
          117,118
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Stem cell factor and FLT3 ligand (FLT3LG)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stem cell factor (SCF) [
         <a href="#rid119">
          119,120
         </a>
         ] and FLT3 ligand (FLT3LG) [
         <a href="#rid121">
          121-123
         </a>
         ], both receptor tyrosine kinase ligands, interact with a variety of hematopoietic progenitor cells, perhaps most importantly with very early stem cell populations  (
         <a class="graphic graphic_figure graphicRef52024" href="/z/d/graphic/52024.html" rel="external">
          figure 1
         </a>
         ). SCF also plays an important role in melanocyte growth and development, which is reflected in the coat color effects of mutations in SCF or its receptor, Kit [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
         Mice defective in either Scf (Sl mice) or Kit (W mice) have serious hematopoietic defects including macrocytic anemia, mast cell deficiencies, and deficiencies in the stem cell compartment [
         <a href="#rid119">
          119
         </a>
         ]. In vitro, the proliferative activity of SCF with hematopoietic cells is minimal alone, largely yielding mast cells [
         <a href="#rid124">
          124
         </a>
         ] and is generally most evident when combined with other hematopoietic growth factors (HGFs) [
         <a href="#rid119">
          119
         </a>
         ]. It is particularly effective when combined with HGFs such as IL-3, IL-1 or IL-11 in promoting the expansion of "blast" like cells that retain considerable potential for yielding multilineage colonies in secondary culture [
         <a href="#rid125">
          125-127
         </a>
         ].
        </p>
        <p>
         The FLT3 receptor tyrosine kinase was originally identified as a novel receptor present in hematopoietic stem cells; in human marrow, its expression is largely limited to the CD34+ cell population [
         <a href="#rid128">
          128-130
         </a>
         ]. FLT3LG alone yields low numbers of CFU-GM colonies from human bone marrow but acts synergistically with other cytokines including IL-3, GM-CSF, erythropoietin, and SCF to yield enhanced colony formation, both in terms of size and numbers of colonies [
         <a href="#rid122">
          122,131,132
         </a>
         ]. The synergy observed between FLT3LG and the other HGFs is comparable to that observed with SCF in similar systems with the exception that FLT3LG has little effect on BFU-E [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Homeobox genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The homeobox genes of the
         <em>
          HOXA
         </em>
         and
         <em>
          HOXB
         </em>
         gene clusters are expressed in primitive blood cells and play a role in blood cell differentiation. Disruption of
         <em>
          Hoxa9
         </em>
         in mice leads to a 30 to 40 percent reduction in leukocytes and a blunted PMN response to G-CSF [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          REGULATION OF HEMATOPOIETIC GROWTH FACTOR GENES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many different cell types, including T lymphocytes, monocytes/macrophages, fibroblasts, epithelial cells, and endothelial cells elaborate various hematopoietic growth factors (HGFs), especially following stimulation [
         <a href="#rid134">
          134-137
         </a>
         ]. In addition, conditioned media from murine organ cultures of lung, muscle, thymus, bone shaft, and heart all contain readily detectable levels of many different HGFs and cytokines [
         <a href="#rid138">
          138
         </a>
         ].
        </p>
        <p>
         Serum levels of HGFs under steady-state conditions are very low, but elevate rapidly following systemic administration of agents such as lipopolysaccharide (ie, endotoxin) [
         <a href="#rid138">
          138
         </a>
         ]. Thus, it seems likely that normal hematopoiesis is maintained by low level expression of HGFs locally in the microenvironment of the bone marrow, spleen, and thymus, while systemic circulation of HGFs becomes more important following infection when inflammatory mediators such as IL-1 and TNF-alpha can act as potent stimulators of HGF production by many cell types [
         <a href="#rid139">
          139-141
         </a>
         ]. Because HGF production is closely regulated in most cell types, it may be that binding of hematopoietic cells to stromal cells also activates stromal HGF production, analogous to the induction of IL-6 expression by binding of myeloma cells to stromal fibroblasts [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
         Activation of HGF gene expression by various stimuli has been reported for many different cell types [
         <a href="#rid134">
          134-137
         </a>
         ]. This activation serves to accelerate blood cell production in times of stress such as in response to infection, marrow damage, or severe bleeding. Among the many types of HGF-producing cells, the most prominent include T and B lymphocytes, monocytes/macrophages, and mesodermal cells including fibroblasts, endothelial cells, and epithelial cells.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expression of some of the HGF genes, notably IL-3 and IL-5, is restricted largely to activated T cells [
         <a href="#rid143">
          143-145
         </a>
         ]. Activated T cells also produce GM-CSF [
         <a href="#rid146">
          146
         </a>
         ], M-CSF [
         <a href="#rid147">
          147
         </a>
         ], and IL-6 [
         <a href="#rid148">
          148
         </a>
         ], but these HGFs are produced by many other cells as well, including monocytes, macrophages, and the various mesodermally derived cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         G-CSF is expressed by monocytes/macrophages and the various mesodermally derived cells [
         <a href="#rid137">
          137
         </a>
         ], while the expression of IL-11 is even further restricted, as it does not appear to be made by T cells nor by monocyte/macrophages [
         <a href="#rid149">
          149-151
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stem cell factor (SCF) and FLT3 ligand are broadly expressed in many mesodermal cell types [
         <a href="#rid119">
          119,122,131
         </a>
         ] but thus far, little is known about the regulation of their expression.
        </p>
        <p>
        </p>
        <p>
         The expression of the HGFs and other cytokines is often triggered in cells by exposure to other cytokines or growth factors, leading to the concept that there are complicated interacting networks of cytokines that serve to control and coordinate many physiologic responses [
         <a href="#rid152">
          152,153
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H411989">
         <span class="h1">
          MYELOPOIETIC FEEDBACK LOOPS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mouse models have demonstrated a granulocyte colony-stimulating factor (G-CSF)-dependent feedback loop that ensures neutrophil production, both in the emergency response to infection and in the steady state  (
         <a class="graphic graphic_figure graphicRef97523" href="/z/d/graphic/97523.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid154">
          154
         </a>
         ]. These responses involve G-CSF signals that increase stem and myeloid progenitor proliferation and lead to egress of mature neutrophils from the marrow, the latter achieved by disruption of ligand-receptor interactions through reductions in CXCR4 on the neutrophil surface and CXCL12/SDF-1 in the bone marrow stroma. However, the observations that combined G-CSF and GM-CSF null mice produce neutrophils in the steady state at 20 to 30 percent of normal levels and can increase production in emergencies, such as
         <em>
          Candida albicans
         </em>
         infection, indicate that non-G-CSF mechanisms are important for both responses [
         <a href="#rid155">
          155
         </a>
         ].
        </p>
        <p>
         Studies from mouse models have provided new insights into the importance of the G-CSF response in both emergency and steady-state granulopoiesis. Infectious agents are presented to the immune and hematopoietic systems as pathogen-associated molecular patterns (PAMPs) that are recognized by pathogen-recognition receptors, in particular the Toll-like receptors (TLRs). TLRs are expressed by cells of the innate immune system (NK-T cells, gamma-delta T cells, and Th17 T cells) and also by hematopoietic stem and myeloid progenitor cells [
         <a href="#rid156">
          156-160
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3985.html" rel="external">
          "Toll-like receptors: Roles in disease and therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H412375">
         <span class="h2">
          Emergency myelopoiesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The bacterial cell wall component lipopolysaccharide (LPS) is abundant during systemic infection. LPS binds to TLR4, which through a myeloid differentiation adaptor protein Myd88 causes responsive cells to produce G-CSF. Data from Myd88 conditional knockout mice crossed with a variety of tissue-specific Cre animals showed that endothelial cells, but not hematopoietic cells, hepatocytes, bone marrow stromal cells, or pericytes, are essential for the G-CSF response to LPS [
         <a href="#rid161">
          161
         </a>
         ]. Interestingly, the TLRs expressed on hematopoietic stem and progenitor cells, and TLR ligands such as bacterial LPS, can induce self-renewal in HSCs and bias commitment toward myeloid but not erythroid or megakaryocyte lineages [
         <a href="#rid159">
          159
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H412381">
         <span class="h2">
          Basal myelopoiesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the control of steady-state myelopoiesis is complex and still incompletely understood, evidence is emerging for several positive and negative regulatory loops [
         <a href="#rid162">
          162
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Germ-free (GF) mice have neutrophil counts even lower than G-CSF receptor-null animals, and thus LPS or other stimulatory compounds may be supplied by intestinal commensal bacteria (the microbiome) in the steady state to stimulate granulopoiesis through a positive TLR4 mediated G-CSF production pathway [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Further reduction of neutrophils in GF mice by neutrophil antibody treatment leads to another positive feedback process involving TLR4 and an adaptor protein, TRIF, which results in increased G-CSF production [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a negative feedback loop, tissue macrophages and dendritic cells normally engulf apoptotic neutrophils, which inhibits their secretion of IL-23; this cytokine stimulates innate lymphoid cells to produce IL-17, a cytokine that can stimulate G-CSF expression. Adhesion molecule deficient mice, whose neutrophils cannot transmigrate, show a marked neutrophil leukocytosis and increased levels of G-CSF. The underlying mechanism was shown to involve dis-inhibition of tissue macrophage IL-23 production consequent to decreased neutrophil apoptosis, which thus increases Th17 T cell production of IL-17, leading to G-CSF induction. This led to the hypothesis of a neutrophil "turnstile" mediated by monocyte phagocytosis of transmigrating neutrophils; macrophages thus engaged in apoptosis are postulated to receive anti-inflammatory signals that decrease IL-23 secretion via the nuclear receptors peroxisome proliferator-activator gamma and liver X receptor [
         <a href="#rid163">
          163,164
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These mechanisms are probably the tip of an iceberg that will likely involve numerous pathways in the neutrophil response, not only to different bacterial and fungal PAMPs, but also to exposure in different tissues such as the skin, lung, or gastrointestinal tract, and to other non-infectious signals such as inflammation that can result in altered myelopoiesis.
        </p>
        <p class="headingAnchor" id="H1305306">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Myelopoiesis begins with the differentiation of multipotent hematopoietic stem cells into the most primitive myeloid progenitors. These progenitors develop into myeloid precursors, which follow specific differentiation programs culminating in the emergence of mature neutrophils, eosinophils, basophils, and monocytes  (
         <a class="graphic graphic_figure graphicRef52024" href="/z/d/graphic/52024.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Anatomy of myelopoiesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differentiation
         </strong>
         – Maturation of multipotent stem cells is controlled by expression of successive combinations of transcription factors that in turn dictate the expression of adhesion and hematopoietic growth factor receptors. (See
         <a class="local">
          'Regulators of myelopoiesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cellular contributors
         </strong>
         – The most prominent cells producing hematopoietic growth factors include T lymphocytes, monocytes/macrophages, and other mesodermal cells, such as fibroblasts and endothelial cells. These factors serve to accelerate blood cell production in times of stress such as in response to infection, marrow damage, or severe bleeding. (See
         <a class="local">
          'Regulation of hematopoietic growth factor genes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Growth factors
         </strong>
         – A variety of compounds induce movement of mature neutrophils into the circulation including endotoxin, glucocorticoids, a leukocyte-mobilizing factor derived from the third component of complement (C3e), chemoattractants such as C5a, cytokines such as tumor necrosis factor (TNF)-alpha, granulocyte colony-stimulating factor (G-CSF), and certain androgens. (See
         <a class="local">
          'Anatomy of myelopoiesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pattern recognition receptors
         </strong>
         - Pathogen-associated molecular patterns (PAMPs) that are recognized by pattern recognition receptors, such as Toll-like receptors expressed on both non hematopoietic and hematopoietic cells, dictate both emergency and steady-state myelopoiesis through G-CSF production and through direct effects on hematopoietic stem and myeloid progenitor cells  (
         <a class="graphic graphic_figure graphicRef97523" href="/z/d/graphic/97523.html" rel="external">
          figure 4
         </a>
         ). (See
         <a class="local">
          'Myelopoietic feedback loops'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H175931903">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate wishes to acknowledge contributions of the late Laurence A Boxer, MD as a section editor for this topic.
        </p>
        <p>
         The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pluznik DH, Sachs L. The cloning of normal "mast" cells in tissue culture. J Cell Physiol 1965; 66:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore MA. Humoral regulation of granulopoiesis. Clin Haematol 1979; 8:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haskill JS, Moore MA. Two dimensional cell separation: comparison of embryonic and adult haemopoietic stem cells. Nature 1970; 226:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D. Detection and analysis of human granulocyte--monocyte precursors using semi-solid cultures. Clin Haematol 1979; 8:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olweus J, Lund-Johansen F, Terstappen LW. CD64/Fc gamma RI is a granulo-monocytic lineage marker on CD34+ hematopoietic progenitor cells. Blood 1995; 85:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leary AG, Ogawa M, Strauss LC, Civin CI. Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes. J Clin Invest 1984; 74:2193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wognum AW, Westerman Y, Visser TP, Wagemaker G. Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood 1994; 84:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977; 91:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ATHENS JW, RAAB SO, HAAB OP, et al. Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. J Clin Invest 1961; 40:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cramer E, Pryzwansky KB, Villeval JL, et al. Ultrastructural localization of lactoferrin and myeloperoxidase in human neutrophils by immunogold. Blood 1985; 65:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borregaard N, Kjeldsen L, Lollike K, Sengeløv H. Granules and secretory vesicles of the human neutrophil. Clin Exp Immunol 1995; 101 Suppl 1:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gullberg U, Andersson E, Garwicz D, et al. Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. Eur J Haematol 1997; 58:137.
          </a>
         </li>
         <li class="breakAll">
          Bainton DF. Developmental biology of neutrophils and eosinophils. In: Inflammation Basic Principles and Clinical Correlates, 2nd ed, Raven Press, New York 1992. p.303.
         </li>
         <li>
          <a class="nounderline abstract_t">
           DAVIDSON WM, SMITH DR. A morphological sex difference in the polymorphonuclear neutrophil leucocytes. Br Med J 1954; 2:6.
          </a>
         </li>
         <li class="breakAll">
          Lichtman MA, Chamberlain JK, Weed RI, et al.. The regulation of the release of granulocytes from normal marrow. In: The Granulocyte: Function and Clinical Utilization, Greenwalt TJ, Jamieson GA (Eds), Alan R Liss, New York 1977. p.53.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opdenakker G, Fibbe WE, Van Damme J. The molecular basis of leukocytosis. Immunol Today 1998; 19:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahoz-Beneytez J, Elemans M, Zhang Y, et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood 2016; 127:3431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez-Madrid F, Nagy JA, Robbins E, et al. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J Exp Med 1983; 158:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das J, Sharma A, Jindal A, et al. Leukocyte adhesion defect: Where do we stand circa 2019? Genes Dis 2020; 7:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deinard AS, Page AR. A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood. Br J Haematol 1974; 28:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghebrehiwet B, Müller-Eberhard HJ. C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. J Immunol 1979; 123:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell RH, McClelland RM, Kampschmidt RF. Comparison of neutrophilia induced by leukocytic endogenous mediator and by cobra venom factor. Proc Soc Exp Biol Med 1982; 169:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagels MA, Chambers JD, Arfors KE, Hugli TE. C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood 1995; 85:2900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogel JM, Yankee RA, Kimball HR, et al. The effect of etiocholanolone on granulocyte kinetics. Blood 1967; 30:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtman MA, Weed RI. Alteration of the cell periphery during granulocyte maturation: relationship to cell function. Blood 1972; 39:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirahata T, Bjorkman D, Chamberlain JK. Endotoxin: a twofold effect on bone marrow ultrastructure. Scanning Microsc 1987; 1:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano GF, Lichtman MA. Marrow cell egress. The central interaction of barrier pore size and cell maturation. J Clin Invest 1973; 52:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982; 60:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semerad CL, Liu F, Gregory AD, et al. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lévesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day RB, Link DC. Regulation of neutrophil trafficking from the bone marrow. Cell Mol Life Sci 2012; 69:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop CR, Rothstein G, Ashenbrucker HE, Athens JW. Leukokinetic studies. XIV. Blood neutrophil kinetics in chronic, steady-state neutropenia. J Clin Invest 1971; 50:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 2010; 116:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993; 54:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maianski NA, Mul FP, van Buul JD, et al. Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood 2002; 99:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basu S, Hodgson G, Katz M, Dunn AR. Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. Blood 2002; 100:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol 2010; 31:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992; 90:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Furth R, Raeburn JA, van Zwet TL. Characteristics of human mononuclear phagocytes. Blood 1979; 54:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meuret G. Human monocytopoiesis. Exp Hematol 1974; 2:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas ED, Ramberg RE, Sale GE, et al. Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science 1976; 192:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gale RP, Sparkes RS, Golde DW. Bone marrow origin of hepatic macrophages (Kupffer cells) in humans. Science 1978; 201:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979; 282:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ash P, Loutit JF, Townsend KM. Osteoclasts derived from haematopoietic stem cells. Nature 1980; 283:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr I. The biology of macrophages. Clin Invest Med 1978; 1:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology 2018; 154:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manz MG. Plasmacytoid dendritic cells: origin matters. Nat Immunol 2018; 19:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigues PF, Alberti-Servera L, Eremin A, et al. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells. Nat Immunol 2018; 19:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultze JL, Mass E, Schlitzer A. Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation. Immunity 2019; 50:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasson JC, Weisbart RH, Kaufman SE, et al. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science 1984; 226:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisbart RH, Golde DW, Clark SC, et al. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 1985; 314:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tagoh H, Melnik S, Lefevre P, et al. Dynamic reorganization of chromatin structure and selective DNA demethylation prior to stable enhancer complex formation during differentiation of primary hematopoietic cells in vitro. Blood 2004; 103:2950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefevre P, Lacroix C, Tagoh H, et al. Differentiation-dependent alterations in histone methylation and chromatin architecture at the inducible chicken lysozyme gene. J Biol Chem 2005; 280:27552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goebl MK. The PU.1 transcription factor is the product of the putative oncogene Spi-1. Cell 1990; 61:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klemsz MJ, McKercher SR, Celada A, et al. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990; 61:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pahl HL, Scheibe RJ, Zhang DE, et al. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 1993; 268:5014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pongubala JM, Van Beveren C, Nagulapalli S, et al. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science 1993; 259:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin MK, Koshland ME. Ets-related protein PU.1 regulates expression of the immunoglobulin J-chain gene through a novel Ets-binding element. Genes Dev 1993; 7:2006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang DE, Fujioka K, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol 1994; 14:8085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohaus S, Petrovick MS, Voso MT, et al. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol 1995; 15:5830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steidl U, Rosenbauer F, Verhaak RG, et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 2006; 38:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonadies N, Pabst T, Mueller BU. Heterozygous deletion of the PU.1 locus in human AML. Blood 2010; 115:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang QF, Friedman AD. CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood 2002; 99:2776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992; 80:1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamanaka R, Kim GD, Radomska HS, et al. CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc Natl Acad Sci U S A 1997; 94:6462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang DE, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 1996; 16:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schepers H, Wierenga AT, van Gosliga D, et al. Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood 2007; 110:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang DE, Zhang P, Wang ND, et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 1997; 94:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka T, Akira S, Yoshida K, et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 1995; 80:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J 1995; 14:1932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A 1997; 94:13187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 1996; 93:3444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 1996; 87:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaud J, Scott HS, Escher R. AML1 interconnected pathways of leukemogenesis. Cancer Invest 2003; 21:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyoshi H, Shimizu K, Kozu T, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A 1991; 88:10431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 1993; 13:6336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyoshi H, Kozu T, Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12:2715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu P, Tarlé SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi A, Satake M, Yamaguchi-Iwai Y, et al. Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood 1995; 86:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995; 15:1974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank R, Zhang J, Uchida H, et al. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995; 11:2667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang G, Zhang P, Hirai H, et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet 2008; 40:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci U S A 1993; 90:7153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D, Johnson GR, Burgess AW. Direct stimulation by purified GM-CSF of the proliferation of multipotential and erythroid precursor cells. Blood 1980; 55:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieff CA, Emerson SG, Donahue RE, et al. Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. Science 1985; 230:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D, Nicola NA. Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells. J Cell Physiol 1983; 116:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D, Stanley ER. Haematological effects in mice of partially purified colony stimulating factor (CSF) prepared from human urine. Br J Haematol 1971; 21:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D. Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors. Proc Natl Acad Sci U S A 1991; 88:11310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hercus TR, Thomas D, Guthridge MA, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009; 114:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D, Begley CG, Johnson GR, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnaout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986; 78:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez AF, To LB, Yang YC, et al. Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci U S A 1987; 84:2761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez AF, Nicola NA, Burgess AW, et al. Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors. J Immunol 1983; 131:2983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki S, Kobayashi M, Chiba K, et al. Autocrine production of epithelial cell-derived neutrophil attractant-78 induced by granulocyte colony-stimulating factor in neutrophils. Blood 2002; 99:1863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994; 91:5592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003; 349:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205:2703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo X, Higgs BW, Bay-Jensen AC, et al. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis. Rheumatology (Oxford) 2018; 57:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor PC, Saurigny D, Vencovsky J, et al. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res Ther 2019; 21:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent D, Copley M, Benz C, et al. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin Cancer Res 2008; 14:1926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83:2795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 2002; 116:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander WS, Lyman SD, Wagner EF. Expression of functional c-kit receptors rescues the genetic defect of W mutant mast cells. EMBO J 1991; 10:3683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuji K, Lyman SD, Sudo T, et al. Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. Blood 1992; 79:2855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuji K, Zsebo KM, Ogawa M. Enhancement of murine blast cell colony formation in culture by recombinant rat stem cell factor, ligand for c-kit. Blood 1991; 78:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D, Nicola NA. Direct proliferative actions of stem cell factor on murine bone marrow cells in vitro: effects of combination with colony-stimulating factors. Proc Natl Acad Sci U S A 1991; 88:6239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthews W, Jordan CT, Wiegand GW, et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 1994; 91:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirayama F, Lyman SD, Clark SC, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 1995; 85:1762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence HJ, Helgason CD, Sauvageau G, et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood 1997; 89:1922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990; 65:2185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore MA. Haemopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surv 1990; 9:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78:2791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalf D, Willson TA, Hilton DJ, et al. Production of hematopoietic regulatory factors in cultures of adult and fetal mouse organs: measurement by specific bioassays. Leukemia 1995; 9:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quesenberry PJ, Crittenden RB, Lowry P, et al. In vitro and in vivo studies of stromal niches. Blood Cells 1994; 20:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieff CA, Tsai S, Faller DV. Interleukin 1 induces cultured human endothelial cell production of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1987; 79:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieff CA, Niemeyer CM, Mentzer SJ, Faller DV. Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells. Blood 1988; 72:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84:2269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokota T, Arai N, de Vries J, et al. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells. Immunol Rev 1988; 102:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai KI, Lee F, Miyajima A, et al. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niemeyer CM, Sieff CA, Mathey-Prevot B, et al. Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood 1989; 73:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wimperis JZ, Niemeyer CM, Sieff CA, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. Blood 1989; 74:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerdan C, Razanajaona D, Martin Y, et al. Contributions of the CD2 and CD28 T lymphocyte activation pathways to the regulation of the expression of the colony-stimulating factor (CSF-1) gene. J Immunol 1992; 149:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horii Y, Muraguchi A, Suematsu S, et al. Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. J Immunol 1988; 141:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang YC. Interleukin 11: an overview. Stem Cells 1993; 11:474.
          </a>
         </li>
         <li class="breakAll">
          Turner KJ, Clark SC. Interleukin-11: Biological and Clinical Perspectives. In: Hematopoietic Growth Factors in Clinical Applications, Mertelsmann R, Herrmann F (Eds), Marcel Dekker, New York 1995. p.315.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang L, Yang YC. Regulation of interleukin (IL)-11 gene expression in IL-1 induced primate bone marrow stromal cells. J Biol Chem 1994; 269:32732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazan JF. Neuropoietic cytokines in the hematopoietic fold. Neuron 1991; 7:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bugl S, Wirths S, Radsak MP, et al. Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood 2013; 121:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basu S, Hodgson G, Zhang HH, et al. "Emergency" granulopoiesis in G-CSF-deficient mice in response to Candida albicans infection. Blood 2000; 95:3725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mei J, Liu Y, Dai N, et al. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. J Clin Invest 2012; 122:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westerterp M, Gourion-Arsiquaud S, Murphy AJ, et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012; 11:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelletier M, Maggi L, Micheletti A, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010; 115:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood 2012; 119:2991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boettcher S, Gerosa RC, Radpour R, et al. Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis. Blood 2014; 124:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirths S, Bugl S, Kopp HG. Neutrophil homeostasis and its regulation by danger signaling. Blood 2014; 123:3563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark MA, Huo Y, Burcin TL, et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005; 22:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005; 122:707.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8380 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5884359" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The cloning of normal "mast" cells in tissue culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4164182" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The growth of mouse bone marrow cells in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/158453" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Humoral regulation of granulopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5444626" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Two dimensional cell separation: comparison of embryonic and adult haemopoietic stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/385197" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Detection and analysis of human granulocyte--monocyte precursors using semi-solid cultures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10724173" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A clonogenic common myeloid progenitor that gives rise to all myeloid lineages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7537112" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : CD64/Fc gamma RI is a granulo-monocytic lineage marker on CD34+ hematopoietic progenitor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6511923" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7519073" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/301143" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Conditions controlling the proliferation of haemopoietic stem cells in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13684959" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2981589" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Ultrastructural localization of lactoferrin and myeloperoxidase in human neutrophils by immunogold.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7606861" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Granules and secretory vesicles of the human neutrophil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9150707" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9150707" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13160511" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A morphological sex difference in the polymorphonuclear neutrophil leucocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13160511" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A morphological sex difference in the polymorphonuclear neutrophil leucocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9577095" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The molecular basis of leukocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27136946" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6196430" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32181281" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Leukocyte adhesion defect: Where do we stand circa 2019?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4441465" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/110877" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : C3e: an acidic fragment of human C3 with leukocytosis-inducing activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7063513" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparison of neutrophilia induced by leukocytic endogenous mediator and by cobra venom factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7537984" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6054663" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The effect of etiocholanolone on granulocyte kinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5059645" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Alteration of the cell periphery during granulocyte maturation: relationship to cell function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3659866" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Endotoxin: a twofold effect on bone marrow ultrastructure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4512610" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Marrow cell egress. The central interaction of barrier pore size and cell maturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7046844" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12387736" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12531874" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22045556" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Regulation of neutrophil trafficking from the bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5097574" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Leukokinetic studies. XIV. Blood neutrophil kinetics in chronic, steady-state neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20410504" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8760796" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8409750" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11781253" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12130495" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20620114" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Neutrophil kinetics in health and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1383273" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/454850" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Characteristics of human mononuclear phagocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4452365" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Human monocytopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/775638" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Direct evidence for a bone marrow origin of the alveolar macrophage in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/356266" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bone marrow origin of hepatic macrophages (Kupffer cells) in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/503208" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Epidermal Langerhans cells are derived from cells originating in bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7354855" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Osteoclasts derived from haematopoietic stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/391451" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The biology of macrophages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29313948" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Human dendritic cell subsets: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29925994" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Plasmacytoid dendritic cells: origin matters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29925996" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30784577" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6390681" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2984574" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9226149" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Transcription factors, normal myeloid development, and leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15070670" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Dynamic reorganization of chromatin structure and selective DNA demethylation prior to stable enhancer complex formation during differentiation of primary hematopoietic cells in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15923188" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Differentiation-dependent alterations in histone methylation and chromatin architecture at the inducible chicken lysozyme gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2364426" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The PU.1 transcription factor is the product of the putative oncogene Spi-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2180582" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8095266" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8456286" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8406004" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ets-related protein PU.1 regulates expression of the immunoglobulin J-chain gene through a novel Ets-binding element.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969146" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7565736" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8079170" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15146183" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17041602" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19890096" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Heterozygous deletion of the PU.1 locus in human AML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929766" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1391942" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9177240" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11830484" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8622667" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17475913" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9012825" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7530603" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7744000" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9371821" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565077" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8622955" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8929538" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14966519" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12643014" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : AML1 interconnected pathways of leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795214" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1720541" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8413232" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8334990" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1391946" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8351518" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7605990" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7891692" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8545124" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9054947" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17994017" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8394011" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687716" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Lineage-specific hematopoietic growth factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6965346" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Direct stimulation by purified GM-CSF of the proliferation of multipotential and erythroid precursor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3877981" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6602806" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5122671" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Haematological effects in mice of partially purified colony stimulating factor (CSF) prepared from human urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1722326" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19436055" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7521686" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3484428" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3090106" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3495002" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6605995" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11861308" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Autocrine production of epithelial cell-derived neutrophil attractant-78 induced by granulocyte colony-stimulating factor in neutrophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8171324" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8202532" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7697542" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14695413" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955567" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955570" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9410898" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22150039" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The pathogenesis of rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29069507" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30999929" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7508174" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : The kit ligand, stem cell factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18381929" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8180375" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8145851" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11886377" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Class III receptor tyrosine kinases: role in leukaemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1718741" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Expression of functional c-kit receptors rescues the genetic defect of W mutant mast cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1375116" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1715219" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Enhancement of murine blast cell colony formation in culture by recombinant rat stem cell factor, ligand for c-kit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1712485" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Direct proliferative actions of stem cell factor on murine bone marrow cells in vitro: effects of combination with colony-stimulating factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1648448" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8379461" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Interleukin-6 in biology and medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7507245" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7505204" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7703483" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058712" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3296190" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : The human hematopoietic colony-stimulating factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2189549" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : The colony stimulating factors. Discovery, development, and clinical applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2276116" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Haemopoietic growth factor interactions: in vitro and in vivo preclinical evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1720034" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Granulocyte colony-stimulating factor and its receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7544853" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Production of hematopoietic regulatory factors in cultures of adult and fetal mouse organs: measurement by specific bioassays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7994065" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : In vitro and in vivo studies of stromal niches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3491839" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Interleukin 1 induces cultured human endothelial cell production of granulocyte-macrophage colony-stimulating factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2458780" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7919345" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3284813" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1695833" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Cytokines: coordinators of immune and inflammatory responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2645952" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2676015" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1352526" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Contributions of the CD2 and CD28 T lymphocyte activation pathways to the regulation of the expression of the colony-stimulating factor (CSF-1) gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3261753" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8111307" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Interleukin 11: an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8111307" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Interleukin 11: an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7806493" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Regulation of interleukin (IL)-11 gene expression in IL-1 induced primate bone marrow stromal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3076767" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Multiple actions of interleukin 6 within a cytokine network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1714745" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Neuropoietic cytokines in the hematopoietic fold.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23223360" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845903" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : "Emergency" granulopoiesis in G-CSF-deficient mice in response to Candida albicans infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22326959" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22862945" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19890092" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Evidence for a cross-talk between human neutrophils and Th17 cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16782035" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22246037" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Demand-adapted regulation of early hematopoiesis in infection and inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24990886" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24778154" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Neutrophil homeostasis and its regulation by danger signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15780986" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16143103" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Molecular determinants of crosstalk between nuclear receptors and toll-like receptors.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
